- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01554020
Blood Sugar Take Care and Glucose Metabolism
Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
California
-
San Francisco, California, États-Unis, 94109
- SPRIM
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
SUBJECT INCLUSION CRITERIA: STEP 1
- Age ≥ 18 years
Subject meets American Diabetes Association criteria for diabetes testing in asymptomatic, undiagnosed individuals:
- If age ≥45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia
If age <45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia AND present with at least one of the following risk factors:
- Have a first-degree relative with diabetes
- Habitually physically inactive
- Race is African-American, Hispanic American, Native American, Asian American, or Pacific Islander
- Have delivered a baby weighing >9 lb or have been diagnosed with gestational diabetes mellitus
- Hypertensive (≥140/90)
- Known HDL cholesterol level 35 mg/dl
- Known triglyceride level ≥250 mg/dl
- On previous testing, had impaired glucose tolerance or impaired fasting glucose
- History of vascular disease
- Stable body weight (<5% change) in the last 3 months
- Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
- Able to understand the nature and purpose of the study including potential risks and side effects
- Willing to consent to study participation and to comply with study requirements
SUBJECT EXCLUSION CRITERIA
- Known diabetes (type I or II)
- Recent use (within 2 weeks of screening) of any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose or lipid metabolism
- Recent use (within 4 weeks of screening) of any prescription or OTC medication that significantly affects glucose or lipid metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, systemic corticosteroids, statins, fibrates, niacin, and bile acid sequestrants
- Daily use of nonsteroidal anti-inflammatory drugs (NSAIDS); (daily baby aspirin use acceptable)
- Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
- Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
- Eating disorder
- Polycystic ovary syndrome
- Known allergies to any substance in the study product
- Pregnant or breastfeeding women
- History of alcohol, drug, or medication abuse
- Participation in another study with any investigational product within 3 months of screening
- Recent (<3 months) gastrointestinal surgery or any planned surgery during the treatment period
SUBJECT INCLUSION CRITERIA: STEP 2
1. Fasting glucose between 95 and 130 mg/dl, based on portable glucometer reading
SUBJECT INCLUSION CRITERIA: STEP 3
- Impaired fasting glucose, based on the American Diabetes Association definition of fasting serum glucose between 100 and 125 mg/dl
- Impaired glucose tolerance, based on the American Diabetes Association definition of serum glucose between 140 and 199 mg/dl 2 hours after a 75 g glucose load
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Multiherb product
Herbal product
|
One 1200 mg soft gel capsule administered 3X/day for duration of study
Autres noms:
|
|
Comparateur placebo: Placebo
Maltodextrin control
|
One 1200 mg soft-gel capsule administered 3X/day for duration of study
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Glycémie à jeun
Délai: 12 semaines
|
12 semaines
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Événements indésirables
Délai: 12 semaines
|
12 semaines
|
|
|
Pression artérielle
Délai: 12 semaines
|
12 semaines
|
|
|
Indice de sensibilité à l'insuline
Délai: 12 semaines
|
12 semaines
|
|
|
Insuline à jeun
Délai: 12 semaines
|
12 semaines
|
|
|
Homeostasis Model Assessment of Insulin Resistance
Délai: 12 weeks
|
12 weeks
|
|
|
Quantitative insulin sensitivity check index
Délai: 12 weeks
|
12 weeks
|
|
|
Insulin secretion/insulin resistance index
Délai: 12 weeks
|
12 weeks
|
|
|
Hémoglobine glycosylée (HbA1c)
Délai: 12 semaines
|
12 semaines
|
|
|
High-sensitivity C-reactive protein
Délai: 12 weeks
|
12 weeks
|
|
|
High-molecular weight adiponectin
Délai: 12 weeks
|
12 weeks
|
|
|
Lipids (total cholesterol, HDL, LDL, VLDL, triglycerides)
Délai: 12 weeks
|
12 weeks
|
|
|
Body composition
Délai: 12 weeks
|
height/weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio
|
12 weeks
|
|
WHO Quality of Life Questionnaire
Délai: 12 weeks
|
12 weeks
|
|
|
Comprehensive metabolic panel
Délai: 12 weeks
|
12 weeks
|
|
|
Numération globulaire complète
Délai: 12 semaines
|
12 semaines
|
|
|
Gastrointestinal Symptom Rating Scale
Délai: 12 weeks
|
12 weeks
|
|
|
Pulse
Délai: 12 weeks
|
12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Larry Miller, PhD, Sprim Advanced Life Sciences
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 120216-SUS-NWC-BSS-GP
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .